

# Predictors of *Helicobacter pylori* infectivity, Using Stool Antigen Test in Al- Qurna

**Talib Kadhim Aggar (M.B.Ch.B., FICMS)**

Basrah, Iraq College of Medicine, University of Basrah Lecturer, Department of Medicine

**Rafid AJ Mohammed. (M.B.Ch.B., C.A.B.S. MRCS)**

Basrah, Iraq College of Medicine, University of Basrah Lecturer, Department of surgery

**Abdulahameed Majeed (M.B.Ch. B CABM)**

Alsadr teaching hospital, Basrah, Iraq Head of Department of Medicine

## Abstract

**Aim:** To identify predictors of *Helicobacter pylori* (*H. pylori*) infectivity, Using stool antigen test with its correlations to epigastric abdominal pain and other gastrointestinal symptoms.

**Patients & methods:** Patients from Al Qurna presented to private clinic with epigastric abdominal pain each of them has been screened for *H. pylori* via stool antigen test, after evaluations of other causes of abdominal pain. Data analysis was carried out using SPSS version-15

**Results:** a total of 254 patients 142 (55.9%) were males and 112 (44.1%) were

females were studied. *H. pylori* stool antigen was positive in 69 (27.2 %) and negative in 185 (72.8%) of the studied patients. Gastrointestinal symptoms that were observed included weight loss, loss of appetite (3.6%), heart burn (60.6%), vomiting (28.3%), diarrhea (7.1%), constipation (15.4%) and abdomen distension (24%). In 59.3% of the *H. pylori* antigen positive cases, the duration of epigastric pain was of >two weeks.

**Conclusions:** logistic regression analysis indicated that epigastric abdominal pain of > two weeks and loss of appetite were two significant predictors of *H. Pylori* infection.

**Key word:** *H. pylori*, predictors of infectivity, Al Qurna

## Introduction

Isolation of *H. pylori* in 1983 had revolutionized the history of Gastrointestinal (GIT) medicine. <sup>(1)</sup> *H. pylori* plays a vital role in the aetiology of gastritis especially active antral gastritis, and accounts for 90% of duodenal ulcers and 70% gastric ulcers. <sup>(2)</sup> It also plays a role in the development of gastric mucosa-associated lymphoid tissue (MALT), lymphoma and gastric adenocarcinoma <sup>(3)</sup>.

Thus the prevalence of this microorganism is a determinant of the risk of peptic ulcer and related lesions. In a study reported a prevalence rate of 55.8% among university students. <sup>(4)</sup> The bacteria can be cultivated from stool, vomitus and saliva in normal individual <sup>(5)</sup>.

In neighbouring countries as Saudi Arabia the prevalence of *H. pylori* infection was detected in 61% in asymptomatic subject <sup>(6)</sup> and a comparable result was found in Turkey also (56.6%). <sup>(7)</sup>

Amazing seroprevalence rate of *H. pylori* in asymptomatic subject seen in Bangladesh (92%). The majority of infected subjects are asymptomatic and clinical disease is only observed in minority. <sup>(2)</sup>

The methods currently used for detection of *H. pylori* in man include culture of organism from mucosal biopsy or using isotope based urea breath test <sup>(2)</sup> or *H. pylori* stool antigen test (HPSA T), which is cheap, sensitive and specific in > 95% of patients <sup>(2)</sup> (HPSA T) is useful for follow up after detecting and eradication current infection. <sup>(8)</sup>

The current study was designed to determine the relationship between *H. pylori* stool antigen test, as index of infectivity and its correlation with various epigastric pain and other GIT symptoms (weight loss, loss of appetite, heart burn and regurgitation, vomiting, diarrhea, constipation and abdomen distension). <sup>(2)</sup>

Other variables that may potentially cause GIT diseases including smoking, drinking of alcohol, using drugs like corticosteroids or non steroidal anti inflammatory drugs (NSAID) were also explored.

## Patients and methods

This is a two years' study involving recruitment of patients attended a clinic from October 2012 until January 2014 in Al Qurna district 74 km northwest of Basrah. All patients presented with epigastric abdominal pain were included. Each patient was evaluated for age, gender, GIT symptoms, history of smoking, drinking alcohol and corticosteroids treatment and NSAID use. Investigations were done after clinical examination included abdominal ultrasound for most of patients. Fresh stool sample received from each patient and analyzed for detection of H. pylori antigen. Rapid diagnostic test (chromogenic test) was used to detect Helicobacter pylori in stool samples from (ABON company, China). The principle of this technique depends on presence of antigen (bacterium H. pylori) and antibody from the kit. Stool sample emulsion was put on the kit strip and reacts with antibody to make a color result. The appearance of one red line was regarded as negative and two red lines regarded as positive result (under company instructions).

A brief description of symptom and other variables studied was as follows:

**Weight loss:** The loss of 4.5 kg or > 5% of body weight over a period of 6-12 months. <sup>(9)</sup>

**Loss of appetite:** Reduced desire for eating for at least three days <sup>(9)</sup>

**Heart burn:** The presence of retrosternal burning pain. <sup>(10)</sup>

**Regurgitations:** The presence of sour or bitter tasting fluid coming into mouth. <sup>(10)</sup> **Vomiting** defined as forceful expulsion of gastric content. <sup>(10)</sup>

**Diarrhea:** Passage of frequent stools > three bowel motions per day or change in consistency of the stool. <sup>(11)</sup>

**Constipation** was defined as passage of less than three bowel motions per week or passage of hard stool or stool that is difficult to be evacuated. <sup>(11)</sup>

**Abdominal distension:** Gaseous distension on ultrasonic examination.

**Smoking** was defined as a history of smoking at least one cigarette a week <sup>(11)</sup>

**Drinking of alcohol** was sorted as any regular intake of alcohol

**Corticosteroid treatment** is defined as any recent or concurrent history of oral or injectable intake of corticosteroids like

prednisolone, dexamethasone, betamethasone  
or hydrocortisone.

**Non steroidal anti inflammatory drugs (NSAIDs)** use sorted as recent or old use of the available types like diclofenac, ibuprofen, mefenamic acid, indomethacin, piroxicam or aspirin.

**Positive ultrasound examination described** any abdominal pathology like gall bladder, liver, intestinal, pancreatic or peritoneal diseases.

Statistical analyses were done using Statistical Package for Social Science(SPSS) for windows version 15, logistic regression analysis was done to identify the independent predictors which significantly associated with *H. pylori* infection a *p* value of  $<0.05$  was considered significant.

## Results

Of the 254 patients with epigastric abdominal pain, 142(55.9%) were males and 112(44.1 %) were females. Male: female ratio was **1.26: 1**. The mean age was  $34.2 \pm 11.7$  years (Males=  $24.3 \pm 10.7$ , females =  $34.1 \pm 13.0$ ). The test for *H. pylori* stool antigen (HPSA) was positive in 69(27.2%) patients and negative in 185(72.8%) of the patients. Table 1 shows the

distribution of patients according to various symptoms and the percentage of patients with *H pylori* positive or negative results... The majority of patients with epigastric pain presented with heart burn (60.6%). The other symptoms with relatively higher frequency were vomiting, constipation and feeling of distension. Symptoms with lower frequency were weight loss, loss of appetite, regurgitation and diarrhoea. Smoking was reported by 16.1 % while alcohol was reported by only two patients. Ultrasound examination revealed positive evidence of other pathologies in 7 (2.8%) of the patients only. History of NSAID intake was reported by 6.7% and corticosteroids intake was reported by one patient only. In the Univariate analysis, only three variables were significantly associated with positive *H pylori* results ( $P<0.05$ ). These included age, duration of epigastric pain and loss of appetite. All the others did not show significant association with *H pylori* positivity.

In the logistic regression analysis, age lost its effect as predictor of *H pylori* positivity but duration of epigastric pain and loss of appetite remained strong independent predictors as shown in (Table 2).

**Table (1): Results of H pylori stool antigen in relation to selected patient characteristics**

Characteristics	Patients studied No. % out of total		H pylori positive No. %		P value*
Gender	112	44.1	31	27.7	0.491
Female	142	55.9	38	26.8	
Male	254	100.0	69	100.0	
Total					
Age	19	7.5	9	47.4	0.044
<20	81	31.9	17	21.0	
20-29	75	29.5	17	21.0	
30-39	44	17.3	15	34.1	
40-49	24	9.4	10	41.7	
50-59	11	4.3	1	9.1	
60+					
Duration of pain	100	40.7	19	19.0	0.008
≤2 weeks	146	59.3	47	32.2	
>2 weeks	246	100.0	66	26.8	
Total					
Weight loss	4	1.6	3	75.0	0.057
Present			66	26.4	
absent	250	98.4			
Loss of appetite	9	3.6	6	66.9	0.012
Present	245	96.4	63	25.7	
Absent					
Heart burn	154	60.6	46	29.8	0.057
present	100	39.4	23	23.0	
Absent					
Regurgitation	12	4.7	4	33.3	0.218
present	242	95.3	65	26.9	
absent					
Vomiting	72	28.3	17	23.6	0.092
present	182	71.7	52	28.6	
Absent					
Diarrhea	18	7.1	5	27.8	0.563
present	236	92.9	64	27.1	
Absent					
Constipation	39	15.4	11	28.2	0.151
present	215	84.6	58	27.0	
Absent					
Distension	61	24.0	19	31.1	0.093
present	193	76.0	50	25.9	
Absent					

Smoking					
present	41	16.1	11	26.8	0.563
absent	213	83.9	58	27.2	
NSAID					
present	17	6.7	5	29.4	0.211
Absent	237	93.3	64	27.0	
Corticosteroids					
present	1	0.4	1	100.0	0.272
Absent	253	99.6	68	26.9	
Alcohol drinking					
present	2	0.8	0	0.0	0.530
absent	252	99.2	69	27.4	
Ultrasound exam.					
Positive	7	2.8	2	28.6	0.323
negative	247	97.2	67	27.5	
Total	254	100.0	69	27.5	

\*Based on Chi-squared or Fisher Exact Tests

Table (2) Logistic regression analysis to predict positivity of H pylori

variables	B	S.E.	Wald	df	Sig.	Exp(B)
Age	-.003	.013	.042	1	.839	.997
Gender	.045	.308	.021	1	.885	1.046

Duration of epigastric pain	.108	.052	4.351	1	.037	1.114
Weight loss	2.449	1.729	2.006	1	.157	11.572
Loss of appetite	1.870	.781	5.738	1	.017	6.489
regurgitation	-1.022	1.155	.782	1	.376	.360
Heart burn	.293	.319	.847	1	.357	1.341
vomiting	-.337	.363	.865	1	.352	.714
Abdominal distension	-.040	.226	.032	1	.859	.960

## Discussion

This study suggests no significant variation in the age between patients with (HPSA) positive groups & (HPSA) negative groups & apparently, the age was not predictive of the pattern of infectivity of *H. pylori*.

Although there was some difference in frequency of positive stool test which was remarkable in all age groups (Table1) yet this difference was statistically not significant in the logistic regression analysis. This result is in agreement with a study conducted in

Bangladesh <sup>(12)</sup> but contradicts another study <sup>(13)</sup>. which concluded that *H. pylori* was more common in children and the incidence was declining with age, which may signify some age predilection. Similarly, Chen S et al concluded that *H. pylori* incidence decreases with age. <sup>(14)</sup> Conversely, a Welsh & German study revealed increasing infection with advanced age. <sup>(15,16)</sup> However, in neighboring countries as in Saudi Arabia, *H. pylori* infection is acquired in the early age and the risk of infection increases as the age increased <sup>(6)</sup>

However, our observations confound mostly to adult age groups (account for >90% of studied patients) Table (1) and there was a limited extension to childhood age groups, this prejudice may explain the limited effect of age in this study or the variations with the over mentioned studies may reflect geographic, racial or urban- rural variations.

The present study did not reveal difference in the risk of *H. pylori* positivity in relation to gender. This result was similar to an Indian study which showed also no significant difference in this regard. <sup>(17)</sup> Another study published by de Maretel and Parsonnet (2009) concluded a true relationship of *H. pylori* and male gender <sup>(18)</sup>

Conversely, two other studies reported an increased bacterial load in females suggested a significant female gender predilection to *H. pylori* infection. <sup>(19,20)</sup> Our results may require further studies taking into account the role of social and cultural values or larger sample is required as well as assessing the sex hormone profile in the infected patients. We have clearly seen that no significant association existed between HPSA positivity and each of heart burn and regurgitation. These results were consistent with a study by Laine L et al (2002) who demonstrated also no relationship between *H. pylori* infection and gastroesophageal reflux disease <sup>(21)</sup> yet other studies reported a controversial relationship in this regard <sup>(22)</sup>. However, we cannot exclude such relationship perhaps because of lack in the precise assessment of symptoms like cough, asthma & hoarseness of voice which sometimes a manifestations of gastroesophageal reflux disease <sup>(3)</sup>

Our study did not observe a significant change in body weight among patients with HPSA positive as compared to negative groups, but this result may not be true and was confounded by other weight influencing conditions like endocrine causes physical



activity level and economic status. The result support previous results in a study in New York which reported no significant association between *H. pylori* and overweight<sup>(23)</sup> but contradicts another study in the United Kingdom that showed increase in body weight after successful eradication of *H. pylori*.<sup>(24)</sup>

Evaluation of diarrhea in this study did not significantly reveal evidence of *H. pylori* infection but comparing this result with a German study in 2012 which hypothesized that colonization with *H. pylori* might protect from diarrhea<sup>(16)</sup>. Interestingly a recent study demonstrated remarkable association between diarrhea of irritable bowel syndrome and *H. pylori*.<sup>(25)</sup>

At the present study, the duration of epigastric abdominal pain appeared to be a potential predictor of infectivity ( $p < 0.05$ ) and the duration of the pain was sharply recognized into two groups: a group of  $\leq$  two weeks (40.7%) and group of  $>$  two weeks (59.3%). The duration of epigastric abdominal pain appeared to be related to the *H. pylori* pattern of infectivity. We conclude that persistency of epigastric pain of more than 2 weeks was likely a strong predictor of *H. pylori* infection. These results may be explained by several points among them is the early contraction of infection in early childhood especially in developing countries as in southern parts of Iraq and also the *H. pylori* infection tend to run in a chronic course like chronic gastritis or peptic ulcer. Also, it is well-known that acute phase of the *H.*

*pylori* infection may last for about 2 weeks or less & often asymptomatic & after that become chronic<sup>(26, 27, 28, 29, 30)</sup>. Lastly, the prevalence of *H. pylori* & atrophic gastritis is increased in elderly in some studies<sup>(30, 31)</sup> this point could aid the correlations of long duration of epigastric pain & microorganism infectivity.

Pearce et al reported that is *H. pylori* almost certainly acquired from close contact with infected individual in early childhood and persists for decades to become a major risk factor for the development of gastroduodenal diseases in early adult life.<sup>(27)</sup> Similarly, it was reported that *H. pylori* infection was acquired in early childhood and continued contact would have been required for the establishment of real infection that can last lifelong.<sup>(28)</sup> Malaty in 2007 concluded that the infection was acquired since childhood and appeared in adulthood separated by a period of latency.<sup>(29)</sup>

Kataralis et al suggested that the prevalence of *H. pylori* & atrophic gastritis increased in elderly<sup>(30)</sup>, as we referred to before, where others stated that *H. pylori* infection is rarely observed as acute illness which is asymptomatic but commonly seen as chronic (atrophic or non atrophic gastritis). This explains why long duration is necessary to create these complications.<sup>(31)</sup>

In our study we concluded that loss of appetite was second predictor for *H. pylori* infectivity, this result is in agreement with a recent study<sup>(31)</sup> which showed that the chronic gastritis could induce chronic suppression of ghrelin (appetite stimulating peptide). It is well known that chronic gastritis is often a common presentation of



*H. pylori* infection. Adding to that, chronic gastritis is commonly associated with postprandial pain which consequently suppresses the appetite <sup>(32)</sup>.

To conclude, this study strongly supports the view that patients with epigastric abdominal pain for > two weeks and loss of appetite are very likely to have *H pylori* infection.

#### Acknowledgement

We acknowledge the contribution of Professor Omron S Habib, Department of Community Medicine, and Basrah College of Medicine. His advice and assistance in statistical analysis of the results and reviewing the final draft were valuable to bring this article to its final shape.



## References:

1. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. *Lancet* 1983; 1: 1273-1275.
2. Walker B, Colledge N, Ralston S, Penman I, Penman I, Lees C. Alimentary tract and pancreatic disease in: Penman I, Lee C, Davidson principles & practice of internal medicine Elsevier 22ed, 2014, p851, 872.
3. Kupers E, Blaser M. Acid peptic disease in: Goldman L, Schafer A: Goldman's Cecil Textbook of Medicine 24th ed. 2012. P 887,513-514.
4. Hussien B, Qader S, Ahmed H, Ahmed S. The Prevalence of H pylori among University Students in Iraq. *Indian Journal of Science and Technology* 36340-37557-1-PB.
5. Parsonnet J, Shmueli H, Haggerty T. fecal and oral shedding of *Helicobacter pylori* from Healthy infected adults. *JAMA* 1999; 282(23):2240-2245.
6. Khan M, Ghazi H. *Helicobacter pylori* infection in asymptomatic subjects in Makkah, Saudi Arabia. *Journal of Pakistan Medical Association* 2007; 57(3): 114-117.
7. Özyayın A, the geographic variance of *Helicobacter pylori*. *EMJ Gastroenterol.* 2014; 3: 94-102.
8. Shimoyama T. Stool antigen tests for the management of *Helicobacter pylori* infection. *World J Gastroenterol.* 2013; 19(45): 8188–8191.
9. Walsh T, Attiah E, Long D, Kasper D, Jamesson J, Fauci A. Hauser S Et al. Eating Disorders in: Harrison's principles of internal medicine. McGraw Hill Medical. 18th Edition 2012. P. 636.
10. Talley NJ, O' Connor S. Clinical Examination. A systematic guide to physical diagnosis .6<sup>th</sup> edition [Elsevier Australia](#) ., 2012.P 146
11. Lennon A, Goggins M. Disorders of the small and large intestine. The Johns Hopkins Internal Medicine Board Review. Johns Hopkins, 4th ed 2012, p.213, 218.
12. Lee CS, Kim D, jung CW, Park jy. Prevalence of *Helicobacter pylori* in Bangladesh: Rapid urease test. *The ORION Medical Journal* 2003;16: 104-105
13. Rowland M, Daly S, Vaughan M, Higgins A, Bourke B, Drumm B. Age specific for *Helicobacter pylori*. *Gastroenterology* 2006 130(1); 65.
14. Chen S, Ying L, Kong M, Zhang Y, Li Y. Chen S et al. The Prevalence of *Helicobacter pylori* Infection Decreases with Older Age in Atrophic Gastritis Hindawi Publishing Corporation. *Gastroenterology Research and Practice* 2013; (2013) 3.
15. Sitas F, Forman D, Yarnell J, Burr M, Elwood P, Pedley S, Marks K. *Helicobacter pylori* in relation to age and social class in a population of Welsh men. *Gut* 1991;32: 25-28.
16. Bode G, Rothenbacher D, Brenner H. *Helicobacter pylori* colonization and diarrhoeal illness: results of a population-based cross-sectional study in adults. *European Journal of Epidemiology* 2002, 17:823-827.
17. Adlekha s, Chandha T, Krishnan P, Sumangala B. Prevalence of *Helicobacter Pylori* Infection Among Patients Undergoing Upper Gastrointestinal Endoscopy in a Medical College Hospital in Kerala, India *Ann Med Health Sci Res.* 2013;3(4): 559–563.

18. e Martel C, Parsonnet J. *Helicobacter pylori* and gender: a meta-analysis of population – based prevalence surveys. *Dig Dis Sci* 2006;15(12) :2292-301.
19. Moshkowitz M, Horowitz N, Beit-Or A, Halpern Z, Santo E; Gender-associated differences in urea breath test for *Helicobacter pylori* infection referrals and results among dyspeptic patients. *World J Gastrointest Pathophysiol* 2012; 15(3):80-88.
20. Ohtani M, Garcia A, Rogers A, Ge Z, Taylor N, Xu S. Protective role of 17β-estradiol against the development of *Helicobacter pylori*-induced gastric cancer in INS-GAS mice. *Carcinogenesis* 2007; 28(12):2597-2604.
21. Laine L, Sugg J. Effect of *Helicobacter pylori* eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. *Am J Gastroenterol* 2002; 97: 2992-7.
22. Falk GW. The possible role of *Helicobacter pylori* in GERD. *Semin Gastrointest Dis.* 2001 12(3):186-95.
23. Cho I, Blaser MJ, Francois F, Mathew JP, Ye XY, Goldberg JD, Bini EJ. *Helicobacter pylori* and Overweight Status in the United States: Data from the Third National Health and Nutrition Examination Survey. [Am J Epidemiol](#). 2005; 162(6):579-84.
24. Nwokolo CU, Freshwater DA, O'Hare P, Randevara HS. Plasma ghrelin following cure of *Helicobacter pylori*. *Gut* 2003; 52(5):637-640.
25. Yakoob J, Abbas Z, [Naz S](#), [Islam M](#), [Jafri W](#). Virulence markers of *Helicobacter pylori* in patients with diarrhoea-dominant irritable bowel syndrome. [Br J Biomed Sci](#). 2012; 69(1):6-10.
26. Brooks GF, Carroll KC, Butel JS, Morse SA, Mietzner TA. Jawetz, Melnick, and Adelberg's Medical Microbiology Twenty-Sixth Edition. 2013. Chapter 17 Pp 261-262.
27. Pearce M, Campbell D, Mann K, Parker L, Thomas J. Deprivation, timing of preschool infections and *H. pylori* seropositivity at age 49-51 years: the Newcastle thousand families birth cohort. *BMC Infectious Diseases*, 2013; 13:422.
28. Salih BA. *Helicobacter pylori* Infection in Developing Countries: The Burden for How Long? *The Saudi Journal of Gastroenterology* 2009; 15:201-207.
29. Malaty H. Epidemiology of *Helicobacter pylori* infection *Best Pract Res Clin Gastroenterol* .2007; 21 (2): 205–214.
30. Katelaris P, Seow F, Lin B, Napoli J, Ngu M, and Jones D: Effect of age, *Helicobacter pylori* infection, and gastritis with atrophy on serum gastrin and gastric acid secretion in healthy men. *Gut*.1993; 34(8):1032-1037.
31. Francis D gastritis in: Hauser S, Pardi D, Poterucha J. The Mayo Clinic Gastroenterology and Hepatology Board Review myoclinic scientific press 2008 p32, 71
32. Vo H, Goli S, Gill R, Anderson V, Stefanov D, Xu J: Inverse relation between *Helicobacter pylori* Colonization and obesity in cohort of inner city children, *Helicobacter*. 2015; 20(1):64-8.

## التنبؤ بعدوى الجرثومة المعديّة الحلزونية باستخدام فحص مستضدات البراز في قضاء القرنة

**هدف الدراسة:** تحديد تنبؤ العدوى الجرثومة المعديّة الحلزونية عن طريق اختبار مستضدات البراز وارتباطها مع الام البطن الشرسوفي والأعراض المعديّة المعوية الأخرى.

**المرضى وطرائق العمل:** مرضى من القرنة قدموا الى العيادة الخاصة يعانون من ألم البطن الشرسوفي تم فحص كل واحد منهم عبر اختبار مستضدات البراز للجرثومة المعديّة الحلزونية، بعد تقييم الاسباب الأخرى لألام البطن وأجري تحليل البيانات باستخدام برنامج اس بي اس اس النسخة ١٥.

**النتائج:** تمت دراسة ما مجموعه ٢٥٤ مريضاً، ١٤٢ (٥٥,٩%) من الذكور و ١١٢ (٤٤,١%) من الاناث وكان فحص مستضدات البراز للجرثومة المعديّة الحلزونية ايجابياً في ٦٩ (٢٧,٢%) مريض وسلبياً في ١٨٥ (٧٢,٨%) من المرضى الخاضعين للدراسة. وتشمل الأعراض المعديّة المعوية التي لوحظت كل من، فقدان الوزن، فقدان الشهية (٣,٦%) ، حرقه القلب (٦٠,٦%)، والتقيؤ (٢٨,٣%)، والإسهال (٧,١%)، والإمساك (١٥,٤%) ، وانتفاخ البطن

(٢٤٪) وفي ٥٩,٣٪ من حالات فحص مستضدات البراز الايجابي، كانت لديهم مدة الألم الشرسوفي أكثر من أسبوعين.

**الاستنتاجات:** أشار تحليل الانحدار اللوجستي الى ان ألم البطن الشرسوفي لأكثر من أسبوعين وفقدان الشهية ينبئان بقوة عن الاصابة بالبكتيريا المعوية الحلزونية.